James M. Flanagan

9.4k total citations · 2 hit papers
71 papers, 3.3k citations indexed

About

James M. Flanagan is a scholar working on Molecular Biology, Genetics and Epidemiology. According to data from OpenAlex, James M. Flanagan has authored 71 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 21 papers in Genetics and 12 papers in Epidemiology. Recurrent topics in James M. Flanagan's work include Epigenetics and DNA Methylation (36 papers), RNA modifications and cancer (14 papers) and Genetic Syndromes and Imprinting (9 papers). James M. Flanagan is often cited by papers focused on Epigenetics and DNA Methylation (36 papers), RNA modifications and cancer (14 papers) and Genetic Syndromes and Imprinting (9 papers). James M. Flanagan collaborates with scholars based in United Kingdom, Australia and United States. James M. Flanagan's co-authors include Natalie Shenker, Robert Brown, Artūras Petronis, Axel Schumacher, Sun-Chong Wang, Paolo Vineis, Thomas Tang, Kevin Brennan, Luigi Bouchard and Zachary Kaminsky and has published in prestigious journals such as Cancer Research, Oncogene and Scientific Reports.

In The Last Decade

James M. Flanagan

70 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epigenomic Profiling Reveals DNA-Methylation Changes Associated with Major Psychosis

2008 583 citations Jonathan Mill, Thomas Tang et al. The American Journal of Human Genetics profile →
Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies

2023 76 citations Sarah Bowden, Emmanouil Bouras et al. BMC Medicine profile →

Peers

Countries citing papers authored by James M. Flanagan

Since Specialization

Citations

This map shows the geographic impact of James M. Flanagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James M. Flanagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James M. Flanagan more than expected).

Fields of papers citing papers by James M. Flanagan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James M. Flanagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James M. Flanagan. The network helps show where James M. Flanagan may publish in the future.

Co-authorship network of co-authors of James M. Flanagan

This figure shows the co-authorship network connecting the top 25 collaborators of James M. Flanagan. A scholar is included among the top collaborators of James M. Flanagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James M. Flanagan. James M. Flanagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Protocol of a Scoping Review on the Use of Transactional Data for Early Diagnosis (TRADED-ScR) 2025 ·HRB Open Research ·(unknown), Benjamin Jacob, James M. Flanagan, Patrick Redmond	1
2	Testing Behavioral Messages to Increase Recruitment to Health Research When Embedded Within Social Media Campaigns on Twitter: Web-Based Experimental Study 2023 ·JMIR Formative Research ·Sandro Stoffel, (unknown), Robert Kerrison, (unknown), James M. Flanagan, Yasemin Hirst	1
3	Protocol for a systematic review and meta-analysis of the diagnostic test accuracy of host and HPV DNA methylation in cervical cancer screening and management 2023 ·BMJ Open ·Sarah Bowden, (unknown), Ilkka Kalliala, Maria Paraskevaidi, (unknown), Konstantinos S. Kechagias, (unknown), Evangelos Paraskevaidis, Marc Arbyn, James M. Flanagan, Areti Angeliki Veroniki, Maria Kyrgiou	2
4	H3K4me3 mediates uterine leiomyoma pathogenesis via neuronal processes, synapsis components, proliferation, and Wnt/β-catenin and TGF-β pathways 2023 ·Reproductive Biology and Endocrinology ·(unknown), (unknown), (unknown), Amparo Faus, (unknown), Javier Monleón, Greta Carmona‐Antoñanzas, António Pellicer, James M. Flanagan, Hortensia Ferrero	11
5	Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies breakdown → 2023 ·BMC Medicine ·Sarah Bowden, (unknown), Emmanouil Bouras, Georgios Markozannes, Antonios Athanasiou, (unknown), Konstantinos S. Kechagias, (unknown), Verena Zuber, Marc Chadeau‐Hyam, James M. Flanagan, Konstantinos K. Tsilidis, Ilkka Kalliala, Maria Kyrgiou	76
6	Testing the Effectiveness of an Animated Decision Aid to Improve Recruitment of Control Participants in a Case-Control Study: Web-Based Experiment 2022 ·Journal of Medical Internet Research ·Sandro Stoffel, (unknown), Robert Kerrison, (unknown), James M. Flanagan, Yasemin Hirst	4
7	Cancer Loyalty Card Study (CLOCS): protocol for an observational case–control study focusing on the patient interval in ovarian cancer diagnosis 2020 ·BMJ Open ·(unknown), Yasemin Hirst, Sudha Sundar, Marc Chadeau‐Hyam, James M. Flanagan	9
8	Self-Care Behaviors of Ovarian Cancer Patients Before Their Diagnosis: Proof-of-Concept Study 2018 ·JMIR Cancer ·James M. Flanagan, (unknown), Xin Shi, Yasemin Hirst	9
9	Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues 2015 ·BMC Cancer ·Natalie Shenker, Kirsty Flower, Charlotte S. Wilhelm-Benartzi, Wei Dai, Emma Bell, (unknown), (unknown), Gillian Weaver, Robert Brown, James M. Flanagan	14
10	Temporal Stability and Determinants of White Blood Cell DNA Methylation in the Breakthrough Generations Study 2014 ·Cancer Epidemiology Biomarkers & Prevention ·James M. Flanagan, Mark N. Brook, Nick Orr, Katarzyna Tomczyk, Penny Coulson, Olivia Fletcher, Michael E. Jones, Minouk J. Schoemaker, Alan Ashworth, Anthony J. Swerdlow, Robert Brown, Montserrat García‐Closas	47
11	Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients 2013 ·Annals of Oncology ·James M. Flanagan, Charlotte S. Wilhelm-Benartzi, (unknown), Stan B. Kaye, Robert Brown	32
12	Intragenic ATM Methylation in Peripheral Blood DNA as a Biomarker of Breast Cancer Risk 2012 ·Cancer Research ·Kevin Brennan, Montserrat García‐Closas, Nick Orr, Olivia Fletcher, Michael E. Jones, Alan Ashworth, Anthony J. Swerdlow, Heather Thorne, Elio Ríboli, Paolo Vineis, Miren Dorronsoro, Françoise Clavel‐Chapelon, Salvatore Panico, N. Charlotte Onland‐Moret, Dimitrios Trichopoulos, Rudolf Kaaks, Kay‐Tee Khaw, Robert Brown, James M. Flanagan	118
13	Is There a Link Between Genome-Wide Hypomethylation in Blood and Cancer Risk? 2012 ·Cancer Prevention Research ·Kevin Brennan, James M. Flanagan	81
14	Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival 2011 ·Clinical Cancer Research ·Wei Dai, Jens M. Teodoridis, Constanze Zeller, Janet Graham, (unknown), James M. Flanagan, Euan A. Stronach, David Millan, Nadeem Siddiqui, James Paul, Robert Brown	78
15	Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets 2009 ·Molecular Cancer Therapeutics ·James M. Flanagan, Juan M. Funes, Stephen Henderson, (unknown), Nessa Carey, Chris Boshoff	65
16	Direct jetting approaches for handling stem cells 2009 ·Biomedical Materials ·(unknown), James M. Flanagan, Suwan N. Jayasinghe	19
17	Epigenomic Profiling Reveals DNA-Methylation Changes Associated with Major Psychosis breakdown → 2008 ·The American Journal of Human Genetics ·Jonathan Mill, Thomas Tang, Zachary Kaminsky, Tarang Khare, (unknown), Luigi Bouchard, Peixin Jia, (unknown), James M. Flanagan, Axel Schumacher, Sun-Chong Wang, Artūras Petronis	583
18	Host epigenetic modifications by oncogenic viruses 2006 ·British Journal of Cancer ·James M. Flanagan	43
19	The Epstein–Barr virus nuclear antigen-6 protein co-localizes with EBNA-3 and survival of motor neurons protein 2003 ·Virology ·Kenia G. Krauer, Marion Buck, (unknown), James M. Flanagan, Grace Chojnowski, T B Sculley	14
20	Transfer of chromosome 8 into two breast cancer cell lines 2003 ·Cancer Genetics and Cytogenetics ·Peter J. Wilson, Andrew Cuthbert, Anna Marsh, Jeremy M. Arnold, James M. Flanagan, (unknown), (unknown), Elizabeth Baker, David M. Purdie, Robert F. Newbold, Georgia Chenevix‐Trench	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact